top of page


Canada Disability Benefit applications open this week
Applications for the Canada Disability Benefit (CDB) open this week. If you're eligible for the Disability Tax Credit and you (and your...
PHA Canada
Jun 171 min read
Â
Â
Â


Honouring Andrew Barfoot: A Day of Community, Kindness, and Legacy
On a beautiful June day filled with sunshine and warmth, our community gathered for a special fundraiser in honour of Andrew Barfoot....
Sherry Foster
Jun 102 min read
Â
Â
Â
IV selexipag can be used as a bridging therapy
Pulmonary arterial hypertension patients who take selexipag normally take it orally (as a pill). Sometimes, though, this is temporarily...
PHA Canada
Jun 91 min read
Â
Â
Â


Quick Facts: What is Yutrepia?
What it is Yutrepia is a new drug: an inhaled form of treprostinil, a prostacyclin analogue. It was just approved by the Food and Drug...
PHA Canada
Jun 31 min read
Â
Â
Â


From Diagnosis to Advocacy: Heather’s PAH Journey
I was diagnosed with pulmonary arterial hypertension (PAH) in June 2024. In hindsight, knowing the symptoms as I do now, I might have had...
PHA Canada
May 292 min read
Â
Â
Â


Quick facts: Why was the ZENITH sotatercept study stopped?
The ZENITH study looked at some of the sickest pulmonary arterial hypertension (PAH) patients—those labelled as functional class 3...
PHA Canada
May 282 min read
Â
Â
Â


There's no health without mental health
"A person's mental health significantly influences how they experience pain and suffering associated with chronic disease. It's essential...
PHA Canada
May 272 min read
Â
Â
Â


What's the Canada Disability Benefit?
We asked Liss Cairns, Program Manager at Plan Institute, some questions about the Disability Tax Credit and the new Canada Disability...
PHA Canada
May 271 min read
Â
Â
Â


Speaking for Candice: A Mother’s Plea for PAH Patients
Hello. My name is Denise Rumbolt and I’d like to tell you about my daughter, Candice. Like any mother, I’ll tell you she’s beautiful,...
PHA Canada
May 262 min read
Â
Â
Â
Prostacyclin analogues for CTEPH?
This systemic review summarized the data from six studies that examined whether prostacyclin analogues are safe and useful when used to...
PHA Canada
May 261 min read
Â
Â
Â


Rare But Not Alone: What Canada’s New Drug Strategy Means for People with Pulmonary Arterial Hypertension
Living with a rare disease can feel like walking an unmarked path—isolated, uncertain, and overlooked. For those with pulmonary arterial...
PHA Canada
May 132 min read
Â
Â
Â
Some PAH patients on sotatercept can stop taking prostacyclin analogues
In a small study of 34 pulmonary arterial hypertension (PAH) patients taking triple therapy plus sotatercept, some were able to stop...
PHA Canada
May 121 min read
Â
Â
Â


Sotatercept Is Not Just Another Medication
My name is Cindy Hayman, and I have been living with Pulmonary Arterial Hypertension (PAH) for the past seven years. I am classified as a...
PHA Canada
May 82 min read
Â
Â
Â
PHA Canada Marks World Pulmonary Hypertension Day with National Advocacy Events Calling for Timely Access to Treatment
On May 5, World Pulmonary Hypertension Day , the Pulmonary Hypertension Association of Canada (PHA Canada)Â is calling for urgent action...
PHA Canada
May 52 min read
Â
Â
Â


Left-Sided Heart Disease & Pulmonary Hypertension
I was diagnosed with Pulmonary Hypertension in 2019. After tests & procedures, it was determined I likely had group 2 and 3 PH. Group 2...
Dawn Clarke - patient
May 13 min read
Â
Â
Â
Poverty and isolation are associated with worse pulmonary hypertension outcomes
A 2024 study looked at the association between socioeconomic disadvantage and pulmonary hypertension. In one New York hospital system,...
PHA Canada
Apr 281 min read
Â
Â
Â
New Report Exposes Gaps in BC Medication Coverage
The 2025 BC Medication Coverage Report  is here—and it reveals serious gaps in access to life-saving medications across the province....
PHA Canada
Apr 141 min read
Â
Â
Â
Some PH patients with interstitial lung disease may benefit from oral PAH drugs
Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to...
PHA Canada
Apr 141 min read
Â
Â
Â
ZENITH results published: sotatercept is effective for high-risk PAH patients
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Apr 81 min read
Â
Â
Â
Sotatercept is Now in Active Negotiation at pCPA
There has been significant progress in making sotatercept available to those who need it. Just two months after Health Canada approved it...
PHA Canada
Apr 41 min read
Â
Â
Â
bottom of page
